PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1223485
PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1223485
The global thyroid cancer diagnostics market is projected to register a substantial CAGR of 5.7% from 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Global Thyroid Cancer Diagnostics Market, By Product Type (Instruments, Consumables & Accessories), Test Type (Imaging Test, Blood Test, Biopsy, Others), Cancer type (Papillary Carcinoma, Follicular Carcinoma, Others), Stages (Stage I, Stage II, Stage III, Stage IV), Age Group ( 30-65, 65 and above, 21-29, Below 21), End User (Hospitals, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Others), Distribution Channel (Direct Tender, Retail Sales), Country (U.S., Canada, Mexico, Germany, France, U.K, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, Rest of Middle East and Africa) Industry Trends and Forecast to 2030.
Rising incidence and prevalence of thyroid nodules & cancer
Rising thyroid cancer diagnostic tests rise in product approvals
Rise in healthcare expenditure for cancer diagnosis and treatment
Rising awareness towards thyroid cancer
Canon Inc.
FUJIFILM Holdings Corporation
F. Hoffmann-La Roche Ltd
Quest Diagnostics Incorporated
Illumina
Koninklijke Philips N.V.
Thermo Fisher Scientific Inc.
Siemens Healthcare GmbH
Abbott
General Electric Company
BD
QIAGEN
DIASORIN S.P.A.
Merck KGaA
Hologic
Myriad Genetics Inc.
BIOMERIEUX
FONAR Corp.
Time Medical Holding.
PlexBio.
MinFound Medical Systems Co., Ltd
Medonica Co. LTD
Beijing O&D Biotech Co., Ltd.
SternMed GmbH